A surge in older Americans is quitting weight loss medications due to various side effects and treatment disruptions. Mary Bucklew, a 75-year-old retiree from Delaware, was prescribed the medication Ozempic by her nurse practitioner, which drastically changed her eating habits. Over six months, she lost 25 pounds and felt more energetic, but then her Medicare plan stopped covering it, leaving her to stop taking it.
A growing trend is seen among older adults who take GLP-1s and related medications for diabetes, obesity, and other serious health issues, only to discontinue them within months. This often leads to weight regain and loss of associated health benefits. The FDA has approved several GLP-1s for additional uses beyond treating diabetes and obesity.
The high prevalence of obesity among older adults is a major concern, with the Centers for Disease Control and Prevention stating that nearly 40% of people aged 65 and above are obese. In addition, Type 2 diabetes rates rise significantly with age. Studies have shown that more than half of Americans 65 and up with diabetes discontinue semaglutide within a year.
Side effects such as nausea, vomiting, bloating, diarrhea, and muscle loss can be significant deterrents for patients. Furthermore, the financial burden of these medications is often too high for many people. To address this issue, the Biden administration has capped out-of-pocket payments for prescription medications at $2,100 in 2026.
However, a crucial policy change may not occur until 2027. Medicare would need to amend its original regulations to allow coverage for weight loss drugs. While some doctors argue that obesity is a disease and should be treated as such, the potential expansion of these medications' indications and extent of coverage raises concerns about increased premiums.
A growing trend is seen among older adults who take GLP-1s and related medications for diabetes, obesity, and other serious health issues, only to discontinue them within months. This often leads to weight regain and loss of associated health benefits. The FDA has approved several GLP-1s for additional uses beyond treating diabetes and obesity.
The high prevalence of obesity among older adults is a major concern, with the Centers for Disease Control and Prevention stating that nearly 40% of people aged 65 and above are obese. In addition, Type 2 diabetes rates rise significantly with age. Studies have shown that more than half of Americans 65 and up with diabetes discontinue semaglutide within a year.
Side effects such as nausea, vomiting, bloating, diarrhea, and muscle loss can be significant deterrents for patients. Furthermore, the financial burden of these medications is often too high for many people. To address this issue, the Biden administration has capped out-of-pocket payments for prescription medications at $2,100 in 2026.
However, a crucial policy change may not occur until 2027. Medicare would need to amend its original regulations to allow coverage for weight loss drugs. While some doctors argue that obesity is a disease and should be treated as such, the potential expansion of these medications' indications and extent of coverage raises concerns about increased premiums.